TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36012027

Group type: EXPERIMENTAL
Intervention: 10 weekly food education sessions based on the Transtheoretical model
Number of subjects: 0

Group type: COMPARATOR
Intervention: 3 general educational sessions on food and health
Number of subjects: 0
Study: 33929094

Group type: EXPERIMENTAL
Intervention: Combination of acute HIV infection (AHI) screening, contract partner notification, and social contact referral
Number of subjects: 1230

Group type: COMPARATOR
Intervention: Malawian standard of care: serial rapid serological HIV tests and passive partner referral
Number of subjects: 1230
Study: 35743686

Group type: EXPERIMENTAL
Intervention: Incremental Shuttle Walking Test (ISWT)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 6-Minute Walking Test (6MWT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Comparison of ISWT and 6MWT
Number of subjects: 29
Study: 33029913

Group type: EXPERIMENTAL
Intervention: Musical Vibroacupuncture (MVA)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham Procedure (SP)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Vibroacupuncture (VA)
Number of subjects: 13
Study: 33125517

Group type: EXPERIMENTAL
Intervention: Flumazenil infusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Supportive care (Control)
Number of subjects: 60
Study: 35782066

Group type: EXPERIMENTAL
Intervention: Routine physical therapy with neuromobilization (Group 2)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Routine physical therapy without neuromobilization (Group 1)
Number of subjects: 66
Study: 34571629

Group type: EXPERIMENTAL
Intervention: Vitrectomy with ILM peeling using heavy brilliant blue G (hBBG) staining
Number of subjects: 44

Group type: COMPARATOR
Intervention: No staining (control group)
Number of subjects: 44
Study: 34389984

Group type: EXPERIMENTAL
Intervention: AIM intervention (universal family‐based substance use preventive intervention)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 216
Study: 33543589

Group type: EXPERIMENTAL
Intervention: Free-access alcohol seeking
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Progressive-ratio seeking
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Family history of alcoholism, venturesomeness traits, and disinhibition traits
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Family history of alcoholism, disinhibition traits, and recent drinking history
Number of subjects: 40
Study: 35247530

Group type: EXPERIMENTAL
Intervention: Preterm birth
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Low birth weight
Number of subjects: 507
Study: 32769416

Group type: EXPERIMENTAL
Intervention: Intensive Interdisciplinary Pain Treatment (IIPT)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Multimodal Treatment (MMT)
Number of subjects: 182
Study: 35427469

Group type: EXPERIMENTAL
Intervention: Long-term androgen deprivation (LTAD)
Number of subjects: 354

Group type: COMPARATOR
Intervention: Short-term androgen deprivation (STAD)
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Long-term androgen deprivation (LTAD) in high-risk patients
Number of subjects: 354

Group type: COMPARATOR
Intervention: Short-term androgen deprivation (STAD) in high-risk patients
Number of subjects: 354
Study: 33461621

Group type: EXPERIMENTAL
Intervention: Indoor residual spraying (IRS) with pirimiphos‐methyl
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indoor residual spraying (IRS) with pirimiphos‐methyl on mud walls
Number of subjects: 0
Study: 32003122

Group type: EXPERIMENTAL
Intervention: Endometrial injury (EI)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study: 34314816

Group type: EXPERIMENTAL
Intervention: Combination of education on self-management and ergonomic principles, a prefabricated neoprene splint, hand exercises, and diclofenac sodium gel
Number of subjects: 204

Group type: COMPARATOR
Intervention: Education alone
Number of subjects: 204
Study: 34464780

Group type: EXPERIMENTAL
Intervention: 3OHB infusion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 8
Study: 32187788

Group type: EXPERIMENTAL
Intervention: Advanced pneumatic compression device (APCD), at-home Flexitouch head and neck APCD, used for at least 30 minutes daily
Number of subjects: 205
Study: 34480861

Group type: EXPERIMENTAL
Intervention: Baricitinib (4 mg once daily for up to 14 days)
Number of subjects: 1525

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1525
Study: 32321490

Group type: EXPERIMENTAL
Intervention: Air-polishing with trehalose powder
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sonic scaling
Number of subjects: 10
Study: 34156755

Group type: EXPERIMENTAL
Intervention: Impella
Number of subjects: 54480

Group type: COMPARATOR
Intervention: IABP
Number of subjects: 54480
Study: 33853997

Group type: EXPERIMENTAL
Intervention: Various novel therapeutic interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thrombolysis for treatment of myocardial infarction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antithrombotic therapy, lipid lowering, anti-diabetes, anti-obesity, heart failure treatments
Number of subjects: 0
Study: 35122105

Group type: EXPERIMENTAL
Intervention: pantoprazole
Number of subjects: 2099

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2099
Study: 33530298

Group type: EXPERIMENTAL
Intervention: Nutritional supplement (protein-rich beverage powder fortified with calcium 600 mg, vitamin D 400 IU, and vitamin K 55 mcg per daily serving)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo supplement (low-protein non-fortified isocaloric beverage powder)
Number of subjects: 0
Study: 33764277

Group type: EXPERIMENTAL
Intervention: EPMHSS and counseling intervention
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 74
Study: 36435274

Group type: EXPERIMENTAL
Intervention: WIfI stage 4
Number of subjects: 1568

Group type: COMPARATOR
Intervention: WIfI stages 1-3
Number of subjects: 1568
Study: 34542577

Group type: EXPERIMENTAL
Intervention: iBASIS‐VIPP preemptive intervention plus usual care
Number of subjects: 104

Group type: COMPARATOR
Intervention: usual care only
Number of subjects: 104
Study: 35270660

Group type: EXPERIMENTAL
Intervention: 12-week motor intervention, 60 min per session, twice per week
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 22
Study: 34506246

Group type: EXPERIMENTAL
Intervention: IG-IMRT
Number of subjects: 300

Group type: COMPARATOR
Intervention: 3D-CRT
Number of subjects: 300
Study: 34542061

Group type: EXPERIMENTAL
Intervention: Trunk side flexion exercises
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Trunk draw-in exercises
Number of subjects: 14
Study: 34282598

Group type: EXPERIMENTAL
Intervention: Lisinopril and Verapamil
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lisinopril alone
Number of subjects: 40
Study: 32415471

Group type: EXPERIMENTAL
Intervention: Combined exercise program (three times a week for eight weeks)
Number of subjects: 28
Study: 35486073

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) with 30-g and 60-g donor feces
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo group (own feces)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 164
Study: 33993104

Group type: EXPERIMENTAL
Intervention: Asynchronous telepsychiatry (ATP)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Synchronous telepsychiatry (STP)
Number of subjects: 184
Study: 35670873

Group type: EXPERIMENTAL
Intervention: Gefapixant 300 mg BID for 1 week, followed by gefapixant 600 mg BID for 2 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 32924787

Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrectomy in elderly patients
Number of subjects: 163
Study: 34371102

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for substance use (up to 12 sessions over 14 weeks)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy targeting depression (CBT-D)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Enhanced treatment as usual (ETAU)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for substance use
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Urinalysis for cannabis use
Number of subjects: 95
Study: 35854374

Group type: EXPERIMENTAL
Intervention: Red LED therapy
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Infrared LED therapy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Simulated photobiomodulation (placebo)
Number of subjects: 39
Study: 33624327

Group type: EXPERIMENTAL
Intervention: Cogmed working memory training program
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo program
Number of subjects: 91
Study: 35763041

Group type: EXPERIMENTAL
Intervention: SIRT+sorafenib
Number of subjects: 45

Group type: COMPARATOR
Intervention: sorafenib alone
Number of subjects: 45
Study: 33795167

Group type: EXPERIMENTAL
Intervention: 2 mL of 88% sucrose (SUC)
Number of subjects: 72

Group type: COMPARATOR
Intervention: 2 mL of placebo (PLA)
Number of subjects: 72
Study: 36068213

Group type: EXPERIMENTAL
Intervention: DA (daunorubicin and ara-C)
Number of subjects: 149

Group type: COMPARATOR
Intervention: ADE (ara-C, daunorubicin, and etoposide)
Number of subjects: 149
Study: 34238628

Group type: EXPERIMENTAL
Intervention: Integrated cognitive behavioral therapy (I-CBT)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 111
Study: 36471424

Group type: EXPERIMENTAL
Intervention: Audit feedback and tailored educational and peer support cointervention
Number of subjects: 70

Group type: COMPARATOR
Intervention: Audit feedback alone (control)
Number of subjects: 70
Study: 33173385

Group type: EXPERIMENTAL
Intervention: Combined chemoradiation (CRT)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Concurrent CRT (CCRT)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Tumour size and nodal involvement
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Combined CRT
Number of subjects: 226
Study: 33683572

Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 84

Group type: COMPARATOR
Intervention: MTA
Number of subjects: 84
Study: 33053113

Group type: EXPERIMENTAL
Intervention: Escitalopram (5‐10 mg once per day, orally; n=49)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (n=48)
Number of subjects: 97
Study: 35942814

Group type: EXPERIMENTAL
Intervention: Intermittent tiotropium bromide 5 µg for 7 to 14 days during respiratory tract infections and as-needed albuterol sulfate 0.2 mg (n = 27)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Twice-daily fluticasone propionate 125 µg for 7 to 14 days during respiratory tract infections and as-needed albuterol sulfate 0.2 mg (n = 25)
Number of subjects: 80

Group type: COMPARATOR
Intervention: As-needed albuterol sulfate 0.2 mg alone (n = 28)
Number of subjects: 80
Study: 33951448

Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT) as a first-line treatment
Number of subjects: 771

Group type: COMPARATOR
Intervention: Medical treatment as a first-line treatment
Number of subjects: 771
Study: 32552731

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 68

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 68
Study: 35552375

Group type: EXPERIMENTAL
Intervention: Modified ligation procedure for prolapsed haemorrhoids (MLPPH)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Stapled haemorrhoidectomy (SH)
Number of subjects: 133
Study: 32178692

Group type: EXPERIMENTAL
Intervention: Combination of omega-3 and plant sterols
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34159762

Group type: EXPERIMENTAL
Intervention: Enarodustat 20 mg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Enarodustat 150 mg (supratherapeutic dose)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: (R)-M2 (metabolite of enarodustat)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Moxifloxacin (positive control, 400 mg)
Number of subjects: 54
Study: 33028396

Group type: EXPERIMENTAL
Intervention: Xanthohumol 24 mg/day for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Xanthohumol
Number of subjects: 0
Study: 35501471

Group type: EXPERIMENTAL
Intervention: Weight gain prevention interventions
Number of subjects: 0
Study: 34304146

Group type: EXPERIMENTAL
Intervention: Active tDCS (twice-daily, 20-min, 2-mA for 5 days)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham-tDCS
Number of subjects: 90
Study: 35733213

Group type: EXPERIMENTAL
Intervention: Single-dose denosumab 60 mg subcutaneous injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32686234

Group type: COMPARATOR
Intervention: Guided Bone Regeneration (GBR)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Connective Tissue Graft (CTG)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both GBR and CTG
Number of subjects: 42
Study: 35439647

Group type: EXPERIMENTAL
Intervention: Patient-led surveillance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinician-led surveillance
Number of subjects: 0
Study: 34228066

Group type: EXPERIMENTAL
Intervention: Cytisine (1.5-mg capsules taken 6 times daily for 25 days)
Number of subjects: 1452

Group type: COMPARATOR
Intervention: Varenicline (0.5-mg tablets titrated to 1 mg twice daily for 84 days)
Number of subjects: 1452

Group type: EXPERIMENTAL
Intervention: Cytisine
Number of subjects: 1452

Group type: COMPARATOR
Intervention: Varenicline
Number of subjects: 1452
Study: 32638031

Group type: EXPERIMENTAL
Intervention: TLC-sucrose octasulfate
Number of subjects: 117
Study: 35352968

Group type: EXPERIMENTAL
Intervention: Prenatal care attendance
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Postpartum visit attendance
Number of subjects: 123
Study: 33674988

Group type: EXPERIMENTAL
Intervention: Melatonin 6 mg/day for 12 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 32264947

Group type: EXPERIMENTAL
Intervention: Breastfeeding meditation audio
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 34386838

Group type: EXPERIMENTAL
Intervention: REACH
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: REACH+FAMS
Number of subjects: 506

Group type: COMPARATOR
Intervention: Control
Number of subjects: 506
Study: 33448199

Group type: EXPERIMENTAL
Intervention: Intact group (double bundles of PCL retained)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Partial group (partial resection of the anterior lateral bundle of PCL)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Intact group
Number of subjects: 200

Group type: COMPARATOR
Intervention: Partial group
Number of subjects: 200
Study: 32790486

Group type: EXPERIMENTAL
Intervention: Pelnac
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Integra
Number of subjects: 71
Study: 35330427

Group type: EXPERIMENTAL
Intervention: Mobile app
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional methods
Number of subjects: 10
Study: 32333877

Group type: EXPERIMENTAL
Intervention: 30 mg cinacalcet per day plus 60 mg denosumab subcutaneously every 6 months (combination group)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: 60 mg denosumab subcutaneously every 6 months (denosumab group)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Placebo (placebo group)
Number of subjects: 285
Study: 35415779

Group type: EXPERIMENTAL
Intervention: Wellness education
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CCT
Number of subjects: 0
Study: 34722783

Group type: EXPERIMENTAL
Intervention: Alfredson group (AG)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Silbernagel group (SG)
Number of subjects: 40
Study: 35187164

Group type: EXPERIMENTAL
Intervention: Virtual Reality task for ALS patients, duration 10 minutes, sitting position.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (CG) during the same virtual reality task, duration 10 minutes, sitting position.
Number of subjects: 0
Study: 34318543

Group type: EXPERIMENTAL
Intervention: WeChat follow-up management
Number of subjects: 80

Group type: COMPARATOR
Intervention: Traditional follow-up method
Number of subjects: 80
Study: 32524158

Group type: EXPERIMENTAL
Intervention: Postpartum urinary retention requiring indwelling catheterization
Number of subjects: 5802

Group type: EXPERIMENTAL
Intervention: Nulliparity
Number of subjects: 5802

Group type: EXPERIMENTAL
Intervention: ≥ 2nd-degree obstetrical laceration
Number of subjects: 5802

Group type: EXPERIMENTAL
Intervention: Intermittent catheterization during labor
Number of subjects: 5802
Study: 35685406

Group type: EXPERIMENTAL
Intervention: hUC-MSCs-CM via MN
Number of subjects: 30

Group type: COMPARATOR
Intervention: MN saline
Number of subjects: 30
Study: 33300592

Group type: EXPERIMENTAL
Intervention: Prescribed music group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preferred music group
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-music group
Number of subjects: 0
Study: 34496116

Group type: EXPERIMENTAL
Intervention: Picosecond Nd:YAG laser treatment
Number of subjects: 63
Study: 33003548

Group type: EXPERIMENTAL
Intervention: Energy-restricted diet plus 250 min of exercise per week
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Energy-restricted diet plus 150 min of moderate intensity exercise per week
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Energy-restricted diet alone
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: All groups (energy-restricted diet alone, diet plus 150 min exercise, diet plus 250 min exercise)
Number of subjects: 125
Study: 37753690

Group type: EXPERIMENTAL
Intervention: Niacinamide-containing body emollients alone (T1)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Niacinamide-containing body emollients plus cleansing gel (T2)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Niacinamide-containing body emollients (T1)
Number of subjects: 122
Study: 33373078

Group type: EXPERIMENTAL
Intervention: Personalized Physical Activity intervention with fitness graded Motion Exergames (PAfitME™)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 35551078

Group type: EXPERIMENTAL
Intervention: Integrated Disease Management (IDM)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 280
Study: 33148427

Group type: EXPERIMENTAL
Intervention: Orsiro sirolimus‐eluting stents (SES)
Number of subjects: 1134

Group type: EXPERIMENTAL
Intervention: Synergy everolimus‐eluting stents (EES)
Number of subjects: 1134

Group type: COMPARATOR
Intervention: Resolute Integrity zotarolimus‐eluting stents (RI-ZES)
Number of subjects: 1134

Group type: COMPARATOR
Intervention: Resolute Onyx zotarolimus‐eluting stents (RO-ZES)
Number of subjects: 1134
Study: 32987917

Group type: EXPERIMENTAL
Intervention: Abscisic acid (ABA) treatment for 3 months
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo treatment for 3 months
Number of subjects: 65
Study: 33690962

Group type: EXPERIMENTAL
Intervention: Lesion marginal zone image
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Lesion inner region image
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Posterior echo region image
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Original image
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Fusion of all four types of deep features (original image + three discriminative region images)
Number of subjects: 479
Study: 34438242

Group type: EXPERIMENTAL
Intervention: rs1044457 in CMPK1
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: rs693955 in SLC29A1
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: rs2807312 in TLE4
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: multi-gene model analysis
Number of subjects: 91
Study: 32798050

Group type: EXPERIMENTAL
Intervention: Traffic Light label (TL)
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Health Star Rating (HSR)
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Guideline Daily Amounts (%GDA)
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Nutri-Score (NS)
Number of subjects: 357

Group type: COMPARATOR
Intervention: No-nutritional label (control)
Number of subjects: 357
Study: 34191259

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) for ACS
Number of subjects: 877

Group type: EXPERIMENTAL
Intervention: Clinically relevant bleeding events
Number of subjects: 877
Study: 32243009

Group type: EXPERIMENTAL
Intervention: VasH300 (300 mg CWE/day, n = 32)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: VasH600 (600 mg CWE/day, n = 32)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo (n = 32)
Number of subjects: 96
Study: 35227197

Group type: EXPERIMENTAL
Intervention: Advisory display SmartPilot® View (SPV)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Current standards
Number of subjects: 114
Study: 33207093

Group type: EXPERIMENTAL
Intervention: Golimumab
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 36113537

Group type: EXPERIMENTAL
Intervention: 2 mg bulevirtide with tenofovir disoproxil fumarate (TDF)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 5 mg bulevirtide with TDF
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 10 mg bulevirtide with TDF
Number of subjects: 120

Group type: COMPARATOR
Intervention: TDF alone
Number of subjects: 120
Study: 33768641

Group type: EXPERIMENTAL
Intervention: Skin protection products (various formulations)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (no skin protection product)
Number of subjects: 6
Study: 32746923

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir (ATV/r)
Number of subjects: 0
Study: 34433517

Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light (IPL) treatment
Number of subjects: 86

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 86
Study: 32932257

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 290
Study: 35093646

Group type: EXPERIMENTAL
Intervention: Parametric bootstrap (PB) method
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Generalized linear mixed model with random intercept for clusters
Number of subjects: 400
Study: 33009690

Group type: EXPERIMENTAL
Intervention: Monthly video consultations as an add-on to regular care
Number of subjects: 240

Group type: COMPARATOR
Intervention: Regular care (waitlist-control group)
Number of subjects: 240